The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 29, 2016

Filed:

Feb. 21, 2012
Applicants:

Paul T. Spellman, Portland, OR (US);

Joe W. Gray, Lake Oswego, OR (US);

Anguraj Sadanandam, Pollachi, IN;

Laura M. Heiser, Lake Oswego, OR (US);

William J. Gibb, San Anselmo, CA (US);

Wen-lin Kuo, Lin-Kou Town, TW;

Nicholas J. Wang, Porland, OR (US);

Inventors:

Paul T. Spellman, Portland, OR (US);

Joe W. Gray, Lake Oswego, OR (US);

Anguraj Sadanandam, Pollachi, IN;

Laura M. Heiser, Lake Oswego, OR (US);

William J. Gibb, San Anselmo, CA (US);

Wen-lin Kuo, Lin-Kou Town, TW;

Nicholas J. Wang, Porland, OR (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/437 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57484 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/437 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract

Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.


Find Patent Forward Citations

Loading…